GNBT PPS Set to Rocket on US Legalization of Industrial Hemp in Pending Passage of 2018 Farm Act
November 28 2018 - 10:50AM
InvestorsHub NewsWire
New York, NY -- November 28, 2018 --
InvestorsHub NewsWire -- Generex Biotechnology (GNBT)
is long-term biotech player that has mounted a recent comeback
under new leadership. The company has clinically trialed
pharmaceutical intellectual property (IP) in house and new
leadership is on an acquisition spree expanding the portfolio.
GNBT is differentiating itself from other biotech companies
by also building its own distribution network. The company
has already acquired a small network of pharmacies and clinics with
more in the pipeline. So unlike most biotech’s, GNBT will
have revenue while continuing to develop and trial new
pharmaceuticals, not to mention having their own network for
launching new pharmaceuticals. All of this has taken the GNBT
stock price in recent weeks from the $2 PPS range to flirting with
a $20 PPS. But GNBT’s recent move into cannabidiol (CBD) extracts
announced earlier this week may be the new leadership move that
takes the GNBT stock price into the
stratosphere.
Canadian cannabis stocks such as Canopy
Growth (CGC)
and Tilray (TLRY)
saw their share prices skyrocket on the leadup to recreational
marijuana legalization in Canada. As the cannabis market
continues to mature, it now appears CBD derived products may be a
bigger market opportunity than THC products. And the U.S. is
on the verge of legalizing industrial hemp with hemp being a far
larger source of CBD than marijuana. The U.S. market size
dwarfs the Canadian market size and the legalization of hemp is
likely to launch U.S. CBD stocks on fire surpassing the market caps
of Canadian cannabis stocks. The new leadership at GNBT has
strategically positioned the company to benefit from the what looks
to be the now pending legalization of industrial hemp in the 2018
Farm Bill.
GNBT has been gaining experience for a
longtime now in the cannabis pharmaceutical sector through a
co-development initiative with Scientus Pharma,
Inc., a Canadian cannabis pharmaceutical company financially
backed by Canopy Growth. This week, GNBT made a more
committed move into the U.S. CBD market announcing an agreement to produce therapeutic CBD
Infused Water. GNBT entered into an agreement with one of
the leading CBD beverage producers in the U.S., Puration, Inc.
(PURA),
which was recently courted by a U.S. Fortune 500 brand name
beverage company. The deal comes with access to a patented
cannabis extraction process licensed by PURA and owned by Kali,
Inc. (KALY).
The announcement included a mention that the agreement to produce
the CBD Infused Water was part of an even bigger agreement in the
works. Perhaps GNBT has PURA and KALY in its acquisition
sites. In any case, a passage of the 2018 Farm Act that
includes the legalization of industrial hemp has a very good
possibility of the being the catalyst that takes the GNBT PPS to
Canopy Growth and Tilray levels.
Learn more about Generex at http://www.generex.com/
DISCLAIMER: NextBigTicker.com (NBT)is a third
party publisher and news dissemination service provider. NBT
is NOT affiliated in any manner with any company mentioned herein.
NBT is news dissemination solutions provider and are NOT a
registered broker/dealer/analyst/adviser, holds no investment
licenses and may NOT sell, offer to sell or offer to buy any
security. NBT's market updates, news alerts and corporate
profiles are NOT a solicitation or recommendation to buy, sell or
hold securities. The material in this release is intended to be
strictly informational and is NEVER to be construed or interpreted
as research material. All readers are strongly urged to perform
research and due diligence on their own and consult a licensed
financial professional before considering any level of investing in
stocks. All material included herein is republished content
and details which were previously disseminated by the companies
mentioned in this release or opinion of the writer. NBT is not
liable for any investment decisions by its readers or subscribers.
Investors are cautioned that they may lose all or a portion of
their investment when investing in stocks. NBT has not been
compensated for this release and HOLDS NO SHARES OF ANY
COMPANY NAMED IN THIS RELEASE.
Disclaimer/Safe
Harbor:
This news release contains forward-looking
statements within the meaning of the Securities Litigation Reform
Act. The statements reflect the Company's current views with
respect to future events that involve risks and uncertainties.
Among others, these risks include the expectation that any of the
companies mentioned herein will achieve significant sales, the
failure to meet schedule or performance requirements of the
companies' contracts, the companies' liquidity position, the
companies' ability to obtain new contracts, the emergence of
competitors with greater financial resources and the impact of
competitive pricing. In the light of these uncertainties, the
forward-looking events referred to in this release might not
occur.
Source: www.nextbigticker.com
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From May 2024 to Jun 2024
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Jun 2023 to Jun 2024